Does the media prefer APRE or ATNM?

In the previous week, Aprea Therapeutics had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Aprea Therapeutics and 1 mentions for Actinium Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 0.45 beat Actinium Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Actinium Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer IZTC or APRE?

Aprea Therapeutics has a consensus price target of $3.07, indicating a potential upside of 307.26%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has higher valuation & earnings, IZTC or APRE?

Invizyne Technologies has higher earnings, but lower revenue than Aprea Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A Aprea Therapeutics $290K 32.69 -$12.60M -$1.08 N/A

Do analysts prefer ATYR or APRE?

Aprea Therapeutics has a consensus price target of $3.07, indicating a potential upside of 307.26%. Given Aprea Therapeutics' higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than aTyr Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score aTyr Pharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media prefer ATYR or APRE?

In the previous week, aTyr Pharma had 5 more articles in the media than Aprea Therapeutics. MarketBeat recorded 9 mentions for aTyr Pharma and 4 mentions for Aprea Therapeutics. aTyr Pharma's average media sentiment score of 0.58 beat Aprea Therapeutics' score of 0.45 indicating that aTyr Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment aTyr Pharma 2 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor APRE or KYNB?

In the previous week, Kyntra Bio had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 5 mentions for Kyntra Bio and 4 mentions for Aprea Therapeutics. Kyntra Bio's average media sentiment score of 0.56 beat Aprea Therapeutics' score of 0.45 indicating that Kyntra Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aprea Therapeutics (APRE) Competitors

$0.75 -0.03 (-3.42%)

As of 03:35 PM Eastern

Compare

APRE vs. ATNM, IZTC, ATYR, MDXH, and KYNB

Should you buy Aprea Therapeutics stock or one of its competitors? Aprea Therapeutics's main competitors and comparable companies include Actinium Pharmaceuticals (ATNM), Invizyne Technologies (IZTC), aTyr Pharma (ATYR), MDxHealth (MDXH), and Kyntra Bio (KYNB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aprea Therapeutics compare to Actinium Pharmaceuticals?

Aprea Therapeutics (NASDAQ:APRE) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Aprea Therapeutics has higher earnings, but lower revenue than Actinium Pharmaceuticals. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	32.69	-$12.60M	-$1.08	N/A
Actinium Pharmaceuticals	$35.09M	1.06	-$48.82M	$0.36	3.29

Actinium Pharmaceuticals has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Aprea Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market.

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aprea Therapeutics presently has a consensus price target of $3.07, suggesting a potential upside of 307.26%. Actinium Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 321.94%. Given Actinium Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Aprea Therapeutics had 3 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 4 mentions for Aprea Therapeutics and 1 mentions for Actinium Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 0.45 beat Actinium Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Actinium Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aprea Therapeutics beats Actinium Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Aprea Therapeutics compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

In the previous week, Aprea Therapeutics had 4 more articles in the media than Invizyne Technologies. MarketBeat recorded 4 mentions for Aprea Therapeutics and 0 mentions for Invizyne Technologies. Aprea Therapeutics' average media sentiment score of 0.45 beat Invizyne Technologies' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
Aprea Therapeutics	Neutral

Aprea Therapeutics has a consensus price target of $3.07, indicating a potential upside of 307.26%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

34.2% of Aprea Therapeutics shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Invizyne Technologies has higher earnings, but lower revenue than Aprea Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
Aprea Therapeutics	$290K	32.69	-$12.60M	-$1.08	N/A

Invizyne Technologies has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Invizyne Technologies' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

Summary

Aprea Therapeutics beats Invizyne Technologies on 8 of the 11 factors compared between the two stocks.

How does Aprea Therapeutics compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 5.0% of aTyr Pharma shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aprea Therapeutics has a consensus price target of $3.07, indicating a potential upside of 307.26%. Given Aprea Therapeutics' higher probable upside, analysts clearly believe Aprea Therapeutics is more favorable than aTyr Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

aTyr Pharma has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -47.60% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-95.89%	-69.67%
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%

In the previous week, aTyr Pharma had 5 more articles in the media than Aprea Therapeutics. MarketBeat recorded 9 mentions for aTyr Pharma and 4 mentions for Aprea Therapeutics. aTyr Pharma's average media sentiment score of 0.58 beat Aprea Therapeutics' score of 0.45 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
aTyr Pharma	2 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

aTyr Pharma has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

Aprea Therapeutics has higher revenue and earnings than aTyr Pharma. Aprea Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	155.40	-$74.12M	-$0.62	N/A
Aprea Therapeutics	$290K	32.69	-$12.60M	-$1.08	N/A

Summary

aTyr Pharma beats Aprea Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Aprea Therapeutics compare to MDxHealth?

Aprea Therapeutics (NASDAQ:APRE) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Aprea Therapeutics had 3 more articles in the media than MDxHealth. MarketBeat recorded 4 mentions for Aprea Therapeutics and 1 mentions for MDxHealth. MDxHealth's average media sentiment score of 0.89 beat Aprea Therapeutics' score of 0.45 indicating that MDxHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Aprea Therapeutics	Neutral
MDxHealth	Positive

34.2% of Aprea Therapeutics shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aprea Therapeutics currently has a consensus target price of $3.07, suggesting a potential upside of 307.26%. MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 282.80%. Given Aprea Therapeutics' higher probable upside, research analysts plainly believe Aprea Therapeutics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

MDxHealth has a net margin of -33.46% compared to Aprea Therapeutics' net margin of -4,405.59%. MDxHealth's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%
MDxHealth	-33.46%	N/A	-24.25%

Aprea Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Aprea Therapeutics has higher earnings, but lower revenue than MDxHealth. MDxHealth is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	32.69	-$12.60M	-$1.08	N/A
MDxHealth	$107.88M	0.26	-$33.52M	-$0.72	N/A

Summary

Aprea Therapeutics and MDxHealth tied by winning 7 of the 14 factors compared between the two stocks.

How does Aprea Therapeutics compare to Kyntra Bio?

Aprea Therapeutics (NASDAQ:APRE) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

In the previous week, Kyntra Bio had 1 more articles in the media than Aprea Therapeutics. MarketBeat recorded 5 mentions for Kyntra Bio and 4 mentions for Aprea Therapeutics. Kyntra Bio's average media sentiment score of 0.56 beat Aprea Therapeutics' score of 0.45 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aprea Therapeutics has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market.

Aprea Therapeutics currently has a consensus target price of $3.07, indicating a potential upside of 307.26%. Kyntra Bio has a consensus target price of $37.25, indicating a potential upside of 439.39%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kyntra Bio has a net margin of 2,199.13% compared to Aprea Therapeutics' net margin of -4,405.59%. Kyntra Bio's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-47.60%	-40.97%
Kyntra Bio	2,199.13%	N/A	-47.27%

Kyntra Bio has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	32.69	-$12.60M	-$1.08	N/A
Kyntra Bio	$6.44M	4.34	$183.45M	$45.30	0.15

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Kyntra Bio beats Aprea Therapeutics on 12 of the 16 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.54M	$3.92B	$7.26B	$13.15B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.70	14.08	274.71	25.82
Price / Sales	32.69	1,320.94	681.56	110.71
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	0.50	15.31	10.46	6.32
Net Income	-$12.60M	-$22.86M	$3.49B	$359.77M
7 Day Performance	-0.91%	-2.91%	-1.23%	-0.10%
1 Month Performance	-20.73%	-9.00%	-4.49%	-4.01%
1 Year Performance	-47.88%	31.63%	16.46%	6.23%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	3.2955 of 5 stars	$0.75 -3.4%	$3.07 +307.3%	-45.1%	$9.54M	$290K	N/A	8
ATNM Actinium Pharmaceuticals	1.72 of 5 stars	$1.25 -2.3%	$5.00 +300.0%	-26.5%	$39.30M	$35.09M	N/A	30
IZTC Invizyne Technologies	N/A	$6.28 -0.3%	N/A	-55.9%	$39.26M	N/A	N/A	29	Gap Down
ATYR aTyr Pharma	0.6344 of 5 stars	$0.39 +0.2%	N/A	-64.5%	$38.12M	$190K	N/A	53	Trending News Gap Down
MDXH MDxHealth	2.8259 of 5 stars	$0.67 -4.8%	$2.17 +221.8%	-86.7%	$35.01M	$107.88M	N/A	300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. ATNM, IZTC, ATYR, MDXH, and KYNB

How does Aprea Therapeutics compare to Actinium Pharmaceuticals?

Summary

How does Aprea Therapeutics compare to Invizyne Technologies?

Summary

How does Aprea Therapeutics compare to aTyr Pharma?

Summary

How does Aprea Therapeutics compare to MDxHealth?

Summary

How does Aprea Therapeutics compare to Kyntra Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. ATNM, IZTC, ATYR, MDXH, and KYNB

How does Aprea Therapeutics compare to Actinium Pharmaceuticals?

Which has higher earnings & valuation, APRE or ATNM?

Is APRE or ATNM more profitable?

Which has more risk & volatility, APRE or ATNM?

Do institutionals & insiders hold more shares of APRE or ATNM?

Do analysts rate APRE or ATNM?

Does the media prefer APRE or ATNM?

Summary

How does Aprea Therapeutics compare to Invizyne Technologies?

Does the media favor IZTC or APRE?

Do analysts prefer IZTC or APRE?

Do institutionals & insiders believe in IZTC or APRE?

Which has higher valuation & earnings, IZTC or APRE?

Is IZTC or APRE more profitable?

Summary

How does Aprea Therapeutics compare to aTyr Pharma?

Do insiders and institutionals have more ownership in ATYR or APRE?

Do analysts prefer ATYR or APRE?

Is ATYR or APRE more profitable?

Does the media prefer ATYR or APRE?

Which has more volatility & risk, ATYR or APRE?

Which has stronger valuation & earnings, ATYR or APRE?

Summary

How does Aprea Therapeutics compare to MDxHealth?

Does the media refer more to APRE or MDXH?

Do insiders & institutionals have more ownership in APRE or MDXH?

Do analysts rate APRE or MDXH?

Is APRE or MDXH more profitable?

Which has more volatility & risk, APRE or MDXH?

Which has preferable valuation and earnings, APRE or MDXH?

Summary

How does Aprea Therapeutics compare to Kyntra Bio?

Does the media favor APRE or KYNB?

Which has more risk and volatility, APRE or KYNB?

Do analysts rate APRE or KYNB?

Is APRE or KYNB more profitable?

Which has stronger earnings & valuation, APRE or KYNB?

Do insiders & institutionals believe in APRE or KYNB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools